Showing results (41-50 of 69) with videos related to
Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin LymphomasAjay K Gopal, Ronald Levy, Roch Houot, et al.Journal of Oncology Practice|September 15, 2016
Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With CancerArti Hurria, Chie Akiba, Jerome Kim, et al.Frontiers in Immunology|October 16, 2024
Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapyColton Ladbury, Claire Hao, William Tyler Watkins, et al.American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.Blood Advances|April 4, 2023
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphomaTycel J Phillips, David Bond, Radihka Takiar, et al.The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.Cancer|March 19, 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignanciesGautam Borthakur, Leslie Popplewell, Michael Boyiadzis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaRobert Chen, Alex F Herrera, Jessie Hou, et al.Pageof 7